Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SYDNEY, AUSTRALIA--(Marketwired - Jun 21, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce initial safety data from the first cohort of...
-
SYDNEY, AUSTRALIA--(Marketwired - Jun 6, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock...
-
SYDNEY, AUSTRALIA and SEATTLE, WA--(Marketwired - May 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) Sydys Licenses Clinical-Stage Immuno-oncology Assets in...
-
SYDNEY, AUSTRALIA--(Marketwired - May 1, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number 5908210 entitled "Use of Recombinant...
-
SYDNEY, AUSTRALIA--(Marketwired - Mar 15, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) advises that safety and immune monitoring data from an investigator-led clinical trial in melanoma using...
-
SYDNEY, AUSTRALIA--(Marketwired - Mar 4, 2016) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima," the "Company"), has received notification from the Listing Qualifications Department of The...
-
SHANGHAI, CHINA and SYDNEY, AUSTRALIA--(Marketwired - Mar 2, 2016) - Prima BioMed Ltd. (ASX: PRR) (NASDAQ: PBMD) Highlights First-Ever Chinese-Manufactured...
-
SYDNEY, AUSTRALIA--(Marketwired - Jan 27, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number US 9,244,059 entitled "Cytotoxic...
-
SYDNEY, AUSTRALIA--(Marketwired - Jan 26, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial...
-
SYDNEY, AUSTRALIA--(Marketwired - Dec 22, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) Institutional Review Board Approval Now Obtained at Four Clinical Sites in...